EUSA Pharma (EUSA), a newly-established specialty pharmaceutical business with global reach, has officially launched, following the acquisition of five approved specialty hospital products, a multi-national commercial infrastructure and the EUSA Pharma brand name from Jazz Pharmaceuticals.

The newly-established EUSA is supported by significant funding raised from healthcare growth equity investor Essex Woodlands. EUSA has plans to accelerate its growth through acquisition and in-licensing. 

EUSA Pharma has commercial operations in the U.S and key European markets, and a global distribution network serving approximately 40 other territories. The company has a portfolio of five approved and several named-patient specialty products, which had annual sales of approximately $27 million in 2014. EUSA is working closely with Jazz to provide a smooth transition of the products to ensure patients continue to receive their treatments.

Caphosol is a supersaturated calcium phosphate rinse used as adjunct therapy, alongside standard care, in the treatment and prevention of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy. The product is approved in the U.S., Europe and a number of other territories, including Australia and Hong Kong. 

Collatamp is a lyophilized collagen surgical implant impregnated with the antibiotic gentamicin and is used in hemostasis in surgeries with high risk of infection. It is approved in Europe, South America, the Middle East and Southeast Asia, and a number of other countries including Canada, Australia and New Zealand. EUSA Pharma has global rights to the product outside the U.S.

Custodiol is a pre-prepared solution with a regulatory approval in France for use in the hypothermic storage and preservation of organs for transplantation (heart, kidney, liver and pancreas). 

Fomepizole is a pharmacological antidote approved in a number of European countries for the treatment of poisoning with ethylene glycol, a compound commonly used in antifreeze.

Xenazine is approved for the treatment of movement disorders associated with Huntington's chorea and hemiballismus, and EUSA Pharma has commercial rights to the product in France.

The newly-established EUSA Pharma is headquartered in Hemel Hempstead, U.K., with wholly-owned subsidiaries in the U.S., Germany, France and Holland. The company initially comprises approximately 60 employees, with experts in sales and marketing, medical and regulatory affairs, quality and technical operations. EUSA has ambitious growth plans, and intends to expand its presence in the U.S. and broaden its portfolio through the strategic acquisition and in-licensing of specialty hospital products that it also can leverage through its existing European commercial infrastructure. 

EUSA is led by an experienced management team with a track record of building successful specialty pharmaceutical companies. Chief executive Bryan Morton founded Zeneus Pharma in 2003, which was subsequently sold to Cephalon for $360 million. In 2006, he founded the original transatlantic specialty company EUSA Pharma, which was acquired by Jazz for approximately $700 million. The newly-established EUSA also will be led by chief financial officer Emma Johnson, who has extensive senior level pharmaceutical industry experience in both financial and commercial roles and was a senior member of the EUSA management team, and by chief technical officer Paul Davisson, who has significant experience gained at GlaxoSmithKline, Stryker and EUSA.